Search

Displaying results 161 - 170 of 302 in total
  1. Target

    ATP synthase F(1) complex subunit alpha, mitochondrial

    go.drugbank.com/bio_entities/BE0003840
    TargetHumans

    ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). … Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated

    Polypeptides: ATP synthase F(1) complex subunit alpha, mitochondrial
  2. Target

    Actin-related protein 2/3 complex subunit 1B

    go.drugbank.com/bio_entities/BE0004249
    TargetHumans

    Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:11741539, PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:11741539, PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 1BSynonyms: Arp2/3 complex 41 kDa subunit
  3. Target

    Actin-related protein 2/3 complex subunit 3

    go.drugbank.com/bio_entities/BE0004253
    TargetHumans

    Component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). … The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079).

    Polypeptides: Actin-related protein 2/3 complex subunit 3Synonyms: Arp2/3 complex 21 kDa subunit
  4. Target

    ATP synthase F(0) complex subunit g, mitochondrial

    go.drugbank.com/bio_entities/BE0009022
    TargetHumans

    Part of the complex F(0) domain (PubMed:37244256) … ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256).

    Polypeptides: ATP synthase F(0) complex subunit g, mitochondrial
  5. Indication

    B Vitamin Deficiency

    go.drugbank.com/conditions/DBCOND0067035
    Drugs: Flavin mononucleotide · Hydroxocobalamin · Riboflavin · Saw palmetto
    Synonyms: Vitamin B complex deficiency, B-complex deficiency NOS
  6. Indication

    Ventilator Associated Bacterial Pneumonia (VABP) caused by Acinetobacter Baumannii-calcoaceticus Complex

    go.drugbank.com/conditions/DBCOND0159091
    Drugs: Durlobactam · Sulbactam
    Synonyms: Ventilator Associated Bacterial Pneumonia (VABP) caused by Acinetobacter Baumannii-calcoaceticus Complex
  7. Drug

    Tabirafusp tedromer

    go.drugbank.com/drugs/DB19340
    Investigational

    Tabirafusp tedromer is under investigation in clinical trial NCT06556368 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants

    Synonyms: 3,5,8-Trioxa-4-phosphaundec-10-en-1-aminium,4-hydroxy-N,N,N,10-tetramethyl-9-oxo-, inner salt, 4-oxide, homopolymer,9-arm star compd. with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxy
  8. Drug

    PF-04937319

    go.drugbank.com/drugs/DB15009
    Investigational

    PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).

  9. Target

    B-cell antigen receptor complex-associated protein beta chain

    go.drugbank.com/bio_entities/BE0009680
    TargetHumans

    Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to

    Polypeptides: B-cell antigen receptor complex-associated protein beta chain
  10. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    compare the efficacy of (+) Mefloquine vs. racemic [Mefloquine]. … (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to